defects in Medical Technology

Study Shows How Defective DNA Repair Triggers Two Neurological Diseases

... syndrome (NBS). Both disorders arise from defects in a central component of the cell's machinery ... each disease presents with distinct pathologies. defects in DNA repair dramatically increase the risk of ... of each the diseases to analyze how the gene defects in ATLD and NBS give rise to the different ...

Genzyme Announces Presentation of New Positive Data on Carticel(R)

... who had pain and functional impairment from defects in the articular cartilage of their knee. These ... treated with Carticel for large and multiple defects (4.8 cm2 per lesion and 8.7 cm2 per patient) and ... indicated for the repair of symptomatic cartilage defects of the femoral condyle (medial, lateral ...

American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities

... embryos that present high risk of birth defects or miscarriage for IVF patients AFA supports ... abnormalities that increase the risk of birth defects and miscarriage. "The current technology used to screen embryos for defects analyzes only a small number of chromosomes, ...

Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting

... pre-clinical model at 6 and 12 months. This study indicated that cartilage defects treated with the CRD repaired more rapidly than controls. The data also ... a sophisticated solution for the treatment of focal articular cartilage defects by providing a device with the requisite biomechanical and biological ...

Another Study Links Fluoride to Bone Cancer

... but are downplayed or ignored by government officials.(4)(5) Bone defects similar to bone cancer were detected in fluoridated Newburgh, NY children ... "A radiologist, Dr. John Caffey of Columbia University , called the defects 'striking' in their 'similarity' to bone ... and seen more than ...

Muscadine Grape Skin Dietary Supplement Protects against Cancer Therapy Radiation Side Effects

... In the study reported, Dr. Carsten was able to measure early gene defects in the stem cells in the bone marrow of irradiated mice. These cell ... supplements providers, were optimum for the protective effect against gene defects in normal cells. Karen Wagner, a spokesperson for Muscadine Naturals, ...

AGA Medical Corporation Launches Web-Based Stroke Education and Awareness Program Featuring Professional Football Player Tedy Bruschi

... devices for the minimally invasive treatment of cardiovascular defects and peripheral vascular disease. Founded in 1995 by Dr. Kurt Amplatz, a ... of the most common congenital "holes in the heart", such as atrial septal defects and patent foramen ovales. More than 700 articles have been published ...

Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting

... of patients with myeloproliferative disorders. These JAK2 and MP L defects cause the overproduction of mature malignant blood cells, but multiple ... in five patients with TET2 mutations, which demonstrated that TET2 defects target hematopoietic stem cells. Moreover, they show that in these five ...

Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimer's Disease Announced

... for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital ... for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital ...

Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis

... to evaluate the effects of AC-100 on cartilage regeneration. Cylindrical defects were created in the knee cartilage and were filled with a collagen sponge ... tooth pulp and supports the outer enamel) when applied directly to tooth defects (prepared cavities). "We are very pleased to see this type of response ...

New Research Shows Masimo Perfusion Index (PI) Effective in the Noninvasive Detection of Congenital Heart Defects (CHD) in Newborns

... Masimo SET Perfusion Index (PI) to improve detection of congenital heart defects (CHD) in newborns with duct-dependent systemic circulation. Even when ... PI value cut-offs may help improve the early detection of congenital heart defects that have duct-dependent systemic circulation. As a result, researchers ...

FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function

... in the human heart which are caused by either congenital heart defects or heart attacks. Lemanski, Zhang and their colleagues at FAU have been ... activity levels. In addition, children who are born with congenital heart defects could have those defective areas of their hearts repaired without a series ...

Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease

... for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital ... for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital ...

2,500 Cases Completed With the Magnetic Irrigated Catheter

... from pediatric to geriatric. Included in the Niobe clinical experience are several very compelling procedures in patients with congenital heart defects and patients with peripheral vascular occlusive disease. Altogether this represents the broadest range of cardiovascular applications achieved with ...

Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharma's Product Class

... of those protein synthesis activities. When the mutations found in humans are introduced into the Drosophila genome, the flies develop neurological defects that correspond to CMT in humans. While we are still trying to understand how mutations in the tRNA synthetase gene disrupt the neurological system ...

St. Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients' Heart Structures

... valve surgery. The first mitral valve reconstruction using CorMatrix occurred at St. Francis Heart Center as well, in October of 2008. Large defects had been created in a patient's valve by infection. The valve was restored to normal function using CorMatrix patches, avoiding a valve replacement. ...

Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System

... market acceptance of the product; pricing of any new products; the failure of products to perform as expected, whether due to manufacturing errors, defects or otherwise; the impact of competitive products and pricing; potentially lengthy sales cycles in some markets; reimbursement rates for the products; ...

Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe

... IV (DPP-4) inhibitor for the treatment of type 2 diabetes. By providing complementary mechanisms of action, alogliptin/ACTOS targets the core defects of type 2 diabetes - insulin resistance (when the body does not efficiently use the insulin it produces) and insulin deficiency (when the body does ...

Taking Folic Acid for a Year Before Pregnancy May Reduce Risk of Preterm Birth

... "We already know that folic acid supplementation beginning before pregnancy and continuing into the first trimester helps prevent serious birth defects of the brain and spinal cord, such as spina bifida," said Alan R. Fleischman, M.D., senior vice president and medical director of the March of Dimes. ...

China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit

... variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time. Company Contact: ...

Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin

... sales of the product to be under a compassionate pricing model; the failure of products to perform as expected, whether due to manufacturing errors, defects or otherwise; the impact of competitive products and pricing; potentially lengthy sales cycles in some markets; reimbursement rates for the products; ...

Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting

... therapy. In many, but not all cases, these disorders resolve after stopping PEGINTRON therapy. Use with Ribavirin: Ribavirin may cause birth defects and death of the unborn child. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin ...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

... PRECAUTIONS and ADVERSE REACTIONS in complete product information). Use with Ribavirin . Ribavirin, including COPEGUS(R), may cause birth defects and/or death of the fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes ...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

... and ADVERSE REACTIONS in complete product information). Use with Ribavirin . Ribavirin, including COPEGUS (R) , may cause birth defects and/or death of the fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes ...

Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

... therapy. In many, but not all cases, these disorders resolve after stopping PEGINTRON therapy. Use with Ribavirin: Ribavirin may cause birth defects and death of the unborn child. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin ...

Scientists Discover a Role for the Growth Factor TGF-beta in Maintaining Health of Retinal Blood Vessels

... vessels into the retina tissue, and fluid was leaking out of the vessels, which does not happen when the vessels are functioning properly. These defects led to the death of ganglion cells (nerve cells in the innermost part of the retina) and a loss of visual function. According to D'Amore and ...

FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C

... therapy. In many, but not all cases, these disorders resolve after stopping PEGINTRON therapy. Use with Ribavirin: Ribavirin may cause birth defects and death of the unborn child. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin ...

Scientists Discover Why Teeth Form in a Single Row

... treat malformations and to develop prevention strategies for cleft palate (e.g. the inclusion of folic acid in prenatal vitamins prevents neural tube defects in some cases). Cleft lip/palate occurs one in 700 live births. Along with Jiang, the work was led by Zunyi Zhang and Yu Lan within the Center ...

Applying Clinical Findings to the Practice of Medicine

... ( http://orthoinfo.aaos.org/topic.cfm?topic=A00232 ) and osteoarthritis ( http://orthoinfo.aaos.org/topic.cfm?topic=A00227 ) Skeletal defects Dupuytren's contracture ( http://orthoinfo.aaos.org/topic.cfm?topic=A00008 )and frozen shoulder ( ...

Kensey Nash Announces IDE Submission for Cartilage Repair Device

... to the U.S. Food and Drug Administration (FDA) to study the use of the Company's unique biomaterials technology for treating articular cartilage defects of the knee. The clinical trial will utilize the Company's Cartilage Repair Device, which consists of a proprietary bi-phasic, bioresorbable implant ...

CVBT Opens Florida and Arizona Sites for Its ACORD Phase II Heart Trial

... from peripheral artery disease of the legs. An additional study is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information about CardioVascular BioTherapeutics, Inc. please visit www.cvbt.com . Media Contact: Allison ...

American Dairy Provides Business Update

... variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time. ...

Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer

... been used safely in millions of people as part of a worldwide vaccination program. This strain naturally targets cancer cells due to common genetic defects in cancer cells. JX-594 was engineered to enhance this natural safety and cancer-selectivity by deleting its thymidine kinase (TK) gene, thus making ...

CVBT Opens Two Additional Sites for Patient Enrollment for Phase II Heart Trial

... from peripheral artery disease of the legs. An additional study is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information about CardioVascular BioTherapeutics, Inc. please visit www.cvbt.com . About The ACORD Trial ...

Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL

... parts of chromosomes 13, 11 and 17. The loss of part of chromosome 13 is usually linked with a slower growing disease and a better outlook, while defects in chromosomes 11 or 17 often indicate a poorer outlook. Cytogenetic testing evaluates chromosomes under a microscope to detect any of these ...

CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease

... suffering from peripheral artery disease of the legs. Clinical research is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information about CardioVascular BioTherapeutics, Inc. please visit http://www.cvbt.com . This news release ...

Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C

... but not all cases, these disorders resolve after stopping PEGINTRON and/or INTRON A therapy. Use with Ribavirin: Ribavirin may cause birth defects and/or death of the unborn child. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. ...

Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized 'Moderate Complexity' by FDA

... and methods; customer and market acceptance of the product; the failure of products to perform as expected, whether due to manufacturing errors, defects or otherwise; the impact of competitive products and pricing; reimbursement rates for the products; and underlying market conditions worldwide. ...

Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients

... In many, but not all cases, these disorders resolve after stopping PEGINTRON and/or INTRON A therapy. Use with Ribavirin: Ribavirin may cause birth defects and/or death of the unborn child. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin ...

Breakthrough Mapping of Alzheimer's Genome Helps ID Four New Suspect Genes

... but to also learn from these genes the biological causes of Alzheimer's. The knowledge gained from understanding the Alzheimer's-associated defects in these genes will almost certainly accelerate the development of novel therapeutics and hopefully lead to a potential cure for this devastating ...